Atrial fibrillation: Insights from clinical trials and novel treatment options

Journal of Internal Medicine

Volumn 262, Issue 6, 2007, Pages 593-614

  Blaauw, Y ^a   Crijns, H J G M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atrial fibrillation; Cardiac electrophysiology; Catheter ablation; Clinical pharmacology

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; ATENOLOL; AZD 7009; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ENALAPRIL; FLECAINIDE; IBUTILIDE; IRBESARTAN; LOSARTAN; NIP 142; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PROPAFENONE; RSD 1235; SOTALOL; THROMBIN INHIBITOR; TRANDOLAPRIL; UNCLASSIFIED DRUG; VALSARTAN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CRYOABLATION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART VALVE REPLACEMENT; HUMAN; LUNG FIBROSIS; MORBIDITY; MORTALITY; NEUROPATHY; NONHUMAN; PACEMAKER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; THROMBOEMBOLISM; THYROID DISEASE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC PACING, ARTIFICIAL; CATHETER ABLATION; ELECTRIC COUNTERSHOCK; FIBRINOLYTIC AGENTS; HUMANS; PULMONARY VEINS;

EID: 36349015998     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01885.x     Document Type: Review

References (190)

1. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 271 : 840 4.
2. Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 33.
3. Probst P, Goldschlager N, Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. Circulation 1973 48 : 1282 7.
4. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003 91 : 2D 8D.
5. Stevenson WG, Stevenson LW, Middlekauff HR et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996 28 : 1458 63.
6. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998 98 : 946 52.
7. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004 90 : 286 92.
8. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003 108 : 711 6.
9. Attuel P, Childers R, Cauchemez B et al. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol 1982 2 : 179 97.
10. Wijffels MC, Kirchhof CJ, Dorland R et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995 92 : 1954 68.
11. Garratt CJ, Duytschaever M, Killian M et al. Repetitive electrical remodeling by paroxysms of atrial fibrillation in the goat: no cumulative effect on inducibility or stability of atrial fibrillation. J Cardiovasc Electrophysiol 1999 10 : 1101 8.
12. Franz MR, Karasik PL, Li C et al. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1997 30 : 1785 92.
13. Crijns HJ, van Wijk LM, van Gilst WH et al. Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J 1988 9 : 634 8.
14. Suttorp MJ, Kingma JH, Lie AHL et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 1989 63 : 693 6.
15. Yue L, Feng J, Gaspo R et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997 81 : 512 25.
16. Bosch RF, Zeng X, Grammer JB et al. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res 1999 44 : 121 31.
17. Van Wagoner DR, Pond AL, Lamorgese M et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res 1999 85 : 428 36.
18. Van Wagoner DR, Pond AL, McCarthy PM et al. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997 80 : 772 81.
19. Brandt MC, Priebe L, Bohle T et al. The ultrarapid and the transient outward K(+) current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J Mol Cell Cardiol 2000 32 : 1885 96.
20. Brundel BJ, Van Gelder IC, Henning RH et al. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol 2001 37 : 926 32.
21. Dobrev D, Wettwer E, Kortner A et al. Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res 2002 54 : 397 404.
22. Dobrev D, Graf E, Wettwer E et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation 2001 104 : 2551 7.
23. Brundel BJ, Van Gelder IC, Henning RH et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001 103 : 684 90.
24. Dobrev D, Friedrich A, Voigt N et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005 112 : 3697 706.
25. Ehrlich JR, Cha TJ, Zhang L et al. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J Physiol 2004 557 : 583 97.
26. Li D, Fareh S, Leung TK et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999 100 : 87 95.
27. Verheule S, Sato T, Everett TH et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004 94 : 1458 65.
28. Kostin S, Klein G, Szalay Z et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002 54 : 361 79.
29. Frustaci A, Chimenti C, Bellocci F et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997 96 : 1180 4.
30. Kistler PM, Sanders P, Fynn SP et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol 2004 44 : 109 16.
31. Sanders P, Morton JB, Davidson NC et al. Electrical remodeling of the atria in congestive heart failure. Electrophysiological and electroanatomic mapping in humans. Circulation 2003 108 : 1461 9.
32. Li D, Shinagawa K, Pang L et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001 104 : 2608 14.
33. Kumagai K, Nakashima H, Urata H et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003 41 : 2197 204.
34. Xiao HD, Fuchs S, Campbell DJ et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 2004 165 : 1019 32.
35. Xiao HD, Fuchs S, Frenzel K et al. The use of knockout mouse technology to achieve tissue selective expression of angiotensin converting enzyme. J Mol Cell Cardiol 2004 36 : 781 9.
36. Goette A, Staack T, Rocken C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000 35 : 1669 77.
37. Sugden PH, Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal 1997 9 : 337 51.
38. Urata H, Healy B, Stewart RW et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990 66 : 883 90.
39. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000 71 : 418 35.
40. Lee KS, Marban E, Tsien RW. Inactivation of calcium channels in mammalian heart cells: joint dependence on membrane potential and intracellular calcium. J Physiol 1985 364 : 395 411.
41. Gazmuri RJ, Ayoub IM, Hoffner E et al. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001 104 : 234 9.
42. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999 289 : 211 8.
43. Shihab FS, Bennett WM, Yi H et al. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002 2 : 111 9.
44. Shimizu T, Fukagawa M, Kuroda T et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997 63 : S239 43.
45. Shimizu T, Kuroda T, Hata S et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998 54 : 99 109.
46. Lee KW, Everett TH, Rahmutula D et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006 114 : 1703 12.
47. Mihm MJ, Yu F, Carnes CA et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001 104 : 174 80.
48. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996 271 : C1424 37.
49. Carnes CA, Chung MK, Nakayama T et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 2001 89 : E32 8.
50. Shiroshita-Takeshita A, Schram G, Lavoie J et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004 110 : 2313 9.
51. Shishehbor MH, Brennan ML, Aviles RJ et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003 108 : 426 31.
52. Daoud EG, Knight BP, Weiss R et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 1997 96 : 1542 50.
53. Tieleman RG, De Langen C, Van Gelder IC et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997 95 : 1945 53.
54. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs. Cardiovasc Res 2001 49 : 762 70.
55. Lee SH, Yu WC, Cheng JJ et al. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000 101 : 200 6.
56. Hemels ME, Van Noord T, Crijns HJ et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol 2006 48 : 1001 9.
57. +- exchange inhibbitors on atrial electrical remodeling and atrial fibrillation in the goat. Circulation 2002 106 : II 155.
58. Shinagawa K, Shiroshita-Takeshita A, Schram G et al. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003 107 : 1440 6.
59. Fareh S, Benardeau A, Thibault B et al. The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999 100 : 2191 7.
60. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 40.
61. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003 107 : 2926 31.
62. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999 100 : 376 80.
63. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005 149 : 548 57.
64. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 45 : 712 9.
65. Madrid AH, Bueno MG, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002 106 : 331 6.
66. Milliez P, Deangelis N, Rucker-Martin C et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J 2005 26 : 2193 9.
67. Young-Xu Y, Jabbour S, Goldberg R et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003 92 : 1379 83.
68. Tveit A, Grundtvig M, Gundersen T et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004 93 : 780 2.
69. Ozaydin M, Varol E, Aslan SM et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006 97 : 1490 3.
70. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005 150 : 1064.
71. Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006 114 : 1455 61.
72. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006 27 : 1979 2030.
73. Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996 156 : 2585 92.
74. Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000 102 : 2385 90.
75. Stambler BS, Wood MA, Ellenbogen KA et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation 1996 94 : 1613 21.
76. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000 356 : 1789 94.
77. Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003 41 : 1690 6.
78. Opolski G, Torbicki A, Kosior DA et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004 126 : 476 86.
79. Wijffels MC, Dorland R, Mast F et al. Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000 102 : 260 7.
80. McNamara RL, Tamariz LJ, Segal JB et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003 139 : 1018 33.
81. Reisinger J, Gatterer E, Lang W et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 2004 25 : 1318 24.
82. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 2000 36 : 1 9.
83. Alboni P, Botto GL, Baldi N et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004 351 : 2384 91.
84. Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000 342 : 913 20.
85. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003 42 : 20 9.
86. Singh BN, Singh SN, Reda DJ et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005 352 : 1861 72.
87. Goldschlager N, Epstein AE, Naccarelli G et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000 160 : 1741 8.
88. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990 82 : 1106 16.
89. Flaker GC, Blackshear JL, McBride R et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992 20 : 527 32.
90. Lehmann MH, Hardy S, Archibald D et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996 94 : 2535 41.
91. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999 341 : 857 65.
92. Kober L, Bloch Thomsen PE, Moller M et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000 356 : 2052 8.
93. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994 121 : 529 35.
94. Greene HL, Graham EL, Werner JA et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983 2 : 1114 28.
95. Vorperian VR, Havighurst TC, Miller S et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997 30 : 791 8.
96. Feng J, Wible B, Li GR et al. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res 1997 80 : 572 9.
97. Li GR, Feng J, Yue L et al. Evidence for two components of delayed rectifier K+ current in human ventricular myocytes. Circ Res 1996 78 : 689 96.
98. Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993 73 : 1061 76.
99. Fedida D, Orth PM, Chen JY et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005 16 : 1227 38.
100. Gogelein H, Brendel J, Steinmeyer K et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 2004 370 : 183 92.
101. Goldstein RN, Khrestian C, Carlsson L et al. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004 15 : 1444 50.
102. Matsuda T, Masumiya H, Tanaka N et al. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci 2001 68 : 2017 24.
103. Blaauw Y, Gogelein H, Tieleman RG et al. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004 110 : 1717 24.
104. Wettwer E, Hala O, Christ T et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004 110 : 2299 306.
105. Courtemanche M, Ramirez RJ, Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc Res 1999 42 : 477 89.
106. Blaauw Y, Schotten U, van Hunnik A et al. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res 2007 75 : 89 98.
107. Crijns HJ, Van Gelder IC, Walfridsson H et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 2006 3 : 1321 31.
108. Roy D, Rowe BH, Stiell IG et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004 44 : 2355 61.
109. Cha TJ, Ehrlich JR, Chartier D et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006 113 : 1730 7.
110. Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 2001 10 : 169 77.
111. Peters NS, Coromilas J, Severs NJ et al. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997 95 : 988 96.
112. Wetzel U, Boldt A, Lauschke J et al. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart 2005 91 : 166 70.
113. van der Velden HM, Ausma J, Rook MB et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 2000 46 : 476 86.
114. Nao T, Ohkusa T, Hisamatsu Y et al. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol 2003 91 : 678 83.
115. Kanagaratnam P, Cherian A, Stanbridge RD et al. Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol 2004 15 : 206 16.
116. Gollob MH, Jones DL, Krahn AD et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 2006 354 : 2677 88.
117. Juang JM, Chern YR, Tsai CT et al. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int J Cardiol 2007 116 : 107 12.
118. Muller A, Gottwald M, Tudyka T et al. Increase in gap junction conductance by an antiarrhythmic peptide. Eur J Pharmacol 1997 327 : 65 72.
119. Guerra JM, Everett TH, Lee KW et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 2006 114 : 110 8.
120. Shiroshita-Takeshita A, Sakabe M, Haugan K et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007 115 : 310 8.
121. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967 29 : 469 89.
122. Gallagher MM, Guo XH, Poloniecki JD et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001 38 : 1498 504.
123. Oral H, Souza JJ, Michaud GF et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999 340 : 1849 54.
124. Capucci A, Villani GQ, Aschieri D et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000 21 : 66 73.
125. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998 339 : 659 66.
126. Cappato R, Calkins H, Chen SA et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005 111 : 1100 5.
127. Pappone C, Rosanio S, Oreto G et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000 102 : 2619 28.
128. Friedman PL. Catheter cryoablation of cardiac arrhythmias. Curr Opin Cardiol 2005 20 : 48 54.
129. Oral H, Pappone C, Chugh A et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006 354 : 934 41.
130. Oral H, Scharf C, Chugh A et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 2003 108 : 2355 60.
131. Karch MR, Zrenner B, Deisenhofer I et al. Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. Circulation 2005 111 : 2875 80.
132. Hsu LF, Jais P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 351 : 2373 83.
133. Pappone C, Oral H, Santinelli V et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation 2004 109 : 2724 6.
134. Pappone C, Rosanio S, Augello G et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003 42 : 185 97.
135. Wazni OM, Marrouche NF, Martin DO et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005 293 : 2634 40.
136. Stabile G, Bertaglia E, Senatore G et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006 27 : 216 21.
137. Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991 101 : 584 92.
138. Gaynor SL, Schuessler RB, Bailey MS et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg 2005 129 : 104 11.
139. Cox JL, Ad N, Palazzo T. Impact of the maze procedure on the stroke rate in patients with atrial fibrillation. J Thorac Cardiovasc Surg 1999 118 : 833 40.
140. Gaita F, Riccardi R, Caponi D et al. Linear cryoablation of the left atrium versus pulmonary vein cryoisolation in patients with permanent atrial fibrillation and valvular heart disease: correlation of electroanatomic mapping and long-term clinical results. Circulation 2005 111 : 136 42.
141. Deneke T, Khargi K, Grewe PH et al. Left atrial versus bi-atrial Maze operation using intraoperatively cooled-tip radiofrequency ablation in patients undergoing open-heart surgery: safety and efficacy. J Am Coll Cardiol 2002 39 : 1644 50.
142. Kottkamp H, Hindricks G, Autschbach R et al. Specific linear left atrial lesions in atrial fibrillation: intraoperative radiofrequency ablation using minimally invasive surgical techniques. J Am Coll Cardiol 2002 40 : 475 80.
143. Chiappini B, Martin-Suarez S, LoForte A et al. Cox/Maze III operation versus radiofrequency ablation for the surgical treatment of atrial fibrillation: a comparative study. Ann Thorac Surg 2004 77 : 87 92.
144. Gillinov AM. Advances in surgical treatment of atrial fibrillation. Stroke 2007 2 (Suppl. 618 23.
145. Pruitt JC, Lazzara RR, Dworkin GH et al. Totally endoscopic ablation of lone atrial fibrillation: initial clinical experience. Ann Thorac Surg 2006 81 : 1325 30. discussion 1330-1.
146. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999 131 : 688 95.
147. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. Thromb Res 2006 118 : 321 33.
148. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 22 : 983 8.
149. Jorgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996 27 : 1765 9.
150. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996 27 : 1760 4.
151. Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001 32 : 392 8.
152. Cullinane M, Wainwright R, Brown A et al. Asymptomatic embolization in subjects with atrial fibrillation not taking anticoagulants: a prospective study. Stroke 1998 29 : 1810 5.
153. Ezekowitz MD, James KE, Nazarian SM et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995 92 : 2178 82.
154. Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke 1988 19 : 955 7.
155. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002 288 : 2441 8.
156. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864 70.
157. Go AS, Hylek EM, Chang Y et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003 290 : 2685 92.
158. Hart RG, Pearce LA, Rothbart RM et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000 35 : 183 7.
159. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990 323 : 1505 11.
160. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991 84 : 527 39.
161. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989 1 : 175 9.
162. Connolly SJ, Laupacis A, Gent M et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991 18 : 349 55.
163. Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992 327 : 1406 12.
164. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994 120 : 897 902.
165. Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003 9 (Suppl. S60 3.
166. Schwienhorst A. Direct thrombin inhibitors - a survey of recent developments. Cell Mol Life Sci 2006 63 : 2773 91.
167. Gurm HS, Bhatt DL. Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors. Am Heart J 2005 1 (Suppl. S43 53.
168. Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005 293 : 690 8.
169. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005 353 : 1028 40.
170. Madden J. Resection of the left auricular appendix. JAMA 1948 140 : 768 72.
171. Sick PB, Schuler G, Hauptmann KE et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007 49 : 1490 5.
172. Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005 46 : 9 14.
173. Van Gelder IC, Wyse DG, Chandler ML et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies Europace 2006 8 : 935 42.
174. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Ann Intern Med 1991 114 : 573 5.
175. Shettigar UR, Toole JG, Appunn DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J 1993 126 : 368 74.
176. Delle Karth G, Geppert A, Neunteufl T et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001 29 : 1149 53.
177. Farshi R, Kistner D, Sarma JS et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999 33 : 304 10.
178. Joglar JA, Acusta AP, Shusterman NH et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001 142 : 498 501.
179. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004 44 : 497 502.
180. Bohm M, Schwinger RH, Erdmann E. Different cardiodepressant potency of various calcium antagonists in human myocardium. Am J Cardiol 1990 65 : 1039 41.
181. Olshansky B, Rosenfeld LE, Warner AL et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004 43 : 1201 8.
182. Sellers TD Jr., Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation 1977 56 : 260 7.
183. Crijns HJ, den Heijer P, van Wijk LM et al. Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome. Am Heart J 1988 115 : 1317 21.
184. Rosenquvist M, Lee MA, Moulinier L et al. Long-term follow-up of patients after transcatheter direct current ablation of the atrioventricular junction. J Am Coll Cardiol 1990 16 : 1467 74.
185. Brignole M, Menozzi C, Gianfranchi L et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998 98 : 953 60.
186. Kamalvand K, Tan K, Kotsakis A et al. Is mode switching beneficial? A randomized study in patients with paroxysmal atrial tachyarrhythmias J Am Coll Cardiol 1997 30 : 496 504.
187. Marshall HJ, Harris ZI, Griffith MJ et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation 1999 99 : 1587 92.
188. Doshi RN, Daoud EG, Fellows C et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005 16 : 1160 5.
189. Van Wagoner DR. Electrical Remodeling and Chronic Atrial Fibrillation. In : Zipes DP, Jalife J, eds. Cardiac Electrophysiology. From Cell to Bedside. Philadelphia, PA : Saunders, 2004 375 9.
190. Chugh A, Morady F. Atrial fibrillation: catheter ablation. J Interv Card Electrophysiol 2006 16 : 15 26.